Patient dies in MediGene trial

MediGene (Xetra:MDG) fell EUR 1.34 (22%) to EUR 4.67 on Tuesday after it put a Phase I trial of a new formulation of RhuDex on hold following the death of a volunteer. MediGene said the subject was hospitalized after suffering a heart problem "some days after one of the scheduled treatments of RhuDex." After being discharged, the volunteer died at home. The company said it is investigating the death and that no comparable events occurred in the trial's other 11 volunteers or in previous clinical studies of the DMARD that inhibits CD80. ...